866-997-4948(US-Canada Toll Free)

Nephrotic Syndrome - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 45 Pages

Nephrotic Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nephrotic Syndrome - Pipeline Review, H2 2016, provides an overview of the Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline landscape.

Nephrotic syndrome is a kidney disorder that causes body to excrete too much protein in your urine. Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in kidneys that filter waste and excess water from blood. Symptoms include severe swelling (edema), foamy urine and weight gain due to excess fluid retention. Risk factors include diabetes, lupus, amyloidosis, HIV, hepatitis B, hepatitis C, malaria, certain medications (non-steroidal anti-inflammatory drugs and drugs used to fight infections).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nephrotic Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Nephrotic Syndrome.

Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nephrotic Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Nephrotic Syndrome - Overview 7
Pipeline Products for Nephrotic Syndrome - Comparative Analysis 8
Nephrotic Syndrome - Therapeutics under Development by Companies 9
Nephrotic Syndrome - Therapeutics under Investigation by Universities/Institutes 10
Nephrotic Syndrome - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Nephrotic Syndrome - Products under Development by Companies 14
Nephrotic Syndrome - Products under Investigation by Universities/Institutes 15
Nephrotic Syndrome - Companies Involved in Therapeutics Development 16
AbbVie Inc 16
Asahi Kasei Pharma Corp 17
Bristol-Myers Squibb Company 18
Orbis Biosciences Inc 19
Retrophin Inc 20
Nephrotic Syndrome - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
abatacept - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
atrasentan hydrochloride - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
cosyntropin - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
mizoribine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
prednisone - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Recombinant Proteins to Inhibit Complement C3 for Nephrosis - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SP-20104 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Nephrotic Syndrome - Dormant Projects 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables
Number of Products under Development for Nephrotic Syndrome, H2 2016 7
Number of Products under Development for Nephrotic Syndrome - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Nephrotic Syndrome - Pipeline by AbbVie Inc, H2 2016 16
Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp, H2 2016 17
Nephrotic Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2016 18
Nephrotic Syndrome - Pipeline by Orbis Biosciences Inc, H2 2016 19
Nephrotic Syndrome - Pipeline by Retrophin Inc, H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Nephrotic Syndrome - Dormant Projects, H2 2016 43

List of Figures
Number of Products under Development for Nephrotic Syndrome, H2 2016 7
Number of Products under Development for Nephrotic Syndrome - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Top 10 Targets, H2 2016 22
Number of Products by Stage and Top 10 Targets, H2 2016 22
Number of Products by Top 10 Mechanism of Actions, H2 2016 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 26
Number of Products by Stage and Routes of Administration, H2 2016 26
Number of Products by Molecule Types, H2 2016 28
Number of Products by Stage and Molecule Types, H2 2016 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *